Edgar Filing: Endicott David J.

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â Endicott David J.

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2011

3. Issuer Name and Ticker or Trading Symbol
ALLERGAN INC [AGN]

(Last)

(First)

(Middle)

2525 DUPONT DRIVE

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
CVP and President, AGN Med US

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

IRVINE,Â CAÂ 92612

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	20,186 ⁽¹⁾	D	Â
Common Stock	642.5057 ⁽²⁾	I	By 401(k) Trust
Common Stock	3,104.9626 ⁽³⁾	I	by ESOP Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	Â ⁽⁴⁾	02/14/2018	Common Stock	54,500	$ 64.47	D	Â
Employee Stock Option (Right to Buy)	Â ⁽⁵⁾	02/20/2019	Common Stock	30,000	$ 40.16	D	Â
Employee Stock Option (Right to Buy)	Â ⁽⁶⁾	02/22/2020	Common Stock	37,500	$ 59.13	D	Â
Employee Stock Option (Right to Buy)	Â ⁽⁷⁾	02/17/2021	Common Stock	52,000	$ 75.58	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Endicott David J. 2525 DUPONT DRIVE IRVINE,Â CAÂ 92612	Â	Â	Â CVP and President, AGN Med US	Â

Signatures

Matthew J. Maletta, Attorney-in-fact for David J. Endicott		10/10/2011
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes 7, 577 shares of the Issuer's common stock underlying the Restricted Stock Units awarded to the reporting person.
(2)	Shares allocated to reporting person's SIP account as of reporting date.
(3)	Shares allocated to the reporting person's ESOP account as of reporting date.
(4)	The option became exercisable in four equal annual installment beginning February 14, 2009.
(5)	The option became exercisable in four equal annual installments beginning February 20, 2010. The remaining outstanding options under this award are reported in this filing.
(6)	The option became exercisable in four equal annual installments beginning February 22, 2011. The remaining outstanding options under this award are reported in this filing.
(7)	The option becomes exercisable in four equal annual installments beginning February 17, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.